The GLP-1 questions you should be asking: what to eat, how to train, and when to worry
Microdosing, muscle loss, and the GLP-1 conversation at 40+. What determines if you come out the other side just lighter… or lighter and stronger?
Mounjaro arrived in India in the spring of last year, Wegovy a few months behind it, and suddenly, conversation everywhere referenced this small weekly injection, in clinics, WhatsApp groups, at dinners, and at work. The before-and-afters began circulating, the faces and the figures, the celebrity did-she-or-didn’t-she hypothesising… and it lodged itself in the culture in a way you can’t have failed to notice.
The drugs themselves, the semaglutides and tirzepatides sold here as Ozempic, Wegovy and Mounjaro, belong to a class called GLP-1 receptor agonists, which is a mouthful. GLP-1 is a hormone your gut already releases every time you eat: it prompts your pancreas to make insulin, slows the rate at which your stomach empties, and tells your brain that you have had enough. These injections are a synthetic copy of it, turned up and made to last, so that the body spends the whole week inside a fullness signal it would ordinarily produce only in brief, modest bursts. They were originally formulated for type 2 diabetes, to keep blood sugar in check, and the weight loss arrived as a side effect that soon eclipsed the original purpose.
So it’s a weight-loss drug, you might think? And yes, it is definitely that, but that’s not all it is. The weight loss is the primary benefit that we hear about most, and it has enabled many who’ve struggled with the scales for a lifetime to finally hit their goals, but a scale only tells you how much of you there is, and on these drugs a serious share of what ‘leaves’ is muscle rather than fat.
Whether you should be on one of these is a conversation for you and your doctor, and not the business of this piece. What is certain is that a great many people now are, and that very few of them are being told the next part. That is the part we’re going to focus on here. You can’t replace this medication with food, so all those ‘Nature’s Ozempic’ articles are nothing but clickbait, and nothing you eat can or will do what the injection does, but the point is to eat so the two work together: how much protein you actually need to hold on to your muscle, the easiest everyday ways to get there; the fibre that amplifies the fullness the drug is already creating. Essentially, the small daily habits with real trial evidence behind them, meal timing, the walk after eating, a proper night’s sleep; how to take the edge off the nausea and reflux through the way you eat and not only what; and when something is worth a call to your prescriber. The drug is exceptional at subtraction, but also… indifferent to what it subtracts. The composition of your body, what remains, and whether you reach the far side of this lighter and stronger or lighter and depleted, that’s very much in your hands.
The weight that isn’t fat
The large trials that brought these drugs to market scanned a portion of their participants rather than only weighing them, and the picture underneath the number turned out to be less flattering than the number itself. In one of them, STEP-1, the study that won semaglutide its approval for weight loss, around forty per cent of the weight people lost was lean mass rather than fat, which is to say muscle and the tissue that holds it together. Tirzepatide, the molecule inside Mounjaro, came out a little gentler in SURMOUNT-1, its own equivalent trial, closer to a third. These are averages, and your own split will vary, but across the research, the findings agree: a real and substantial share of what disappears is muscle, unless you give your body a reason to hold on to it.
Take a second here to pause and think about what muscle actually does for you. It is most of what sets your resting metabolic rate, the energy your body spends simply existing, lying still, keeping itself running; it is what gets you up off the floor, what carries the week’s shopping up to a third-floor flat with no lift, what keeps you steady and capable into your sixties and well beyond. And it is, more than almost anything else, what decides whether the weight stays off once you stop, since a body carrying less muscle burns less at rest and slides back into the fat more easily.
Begin with the protein
The first lever, and the one most worth pulling, is (you guessed it) protein (learn how here). The weight-loss research settles on somewhere between 1.2 and 1.6 grams of it per kilo of body weight a day to defend lean mass, which for a woman of around sixty kilos comes to roughly seventy-five to ninety-five grams, a figure that sounds enormous right until you stop picturing chicken breasts and start counting what is already on your plate. A katori of dal, a bowl of dahi, paneer through the sabzi, eggs at breakfast, a fistful of roasted chana: it accumulates faster than the number implies, provided you spread it across the day rather than saving it for one heroic dinner. (The figure comes from a review of forty-nine studies on building muscle while training, where the benefit levelled off around 1.6 grams.)
Spreading it is the actual instruction, because the body can only use so much protein in a single sitting, and twenty to forty grams at each meal does more than the same total amount poured onto one plate at night. On days when the injection flattens your appetite to almost nothing, which it will, the move is to eat the protein first instead of letting your limited appetite be monopolised by the carbs, the rice and the roti. A slowed stomach has its preferences, and they happen to line up with the softest, most ordinary things in an Indian kitchen: the dahi and the dal, the soft paneer, the egg, the fish, the plain glass of milk.
Give the muscle a reason to stay
Protein on its own is only half an instruction. The other half is giving the muscle a reason to remain, which in practice means resistance training, whether that load is a dumbbell, a resistance band looped around a door handle, or simply your own body weight lowered slowly enough to count. The way you train while on a GLP-1 is important, because it’s also the clearest message you can send a body mid-deficit to keep what it has rather than dismantle it for fuel. A European working group on obesity found that strength work, rather than cardio, helped people retain lean mass while dieting. Two or three full-body sessions a week are enough to make the point, and the better measure of whether it is working is how much stronger you are getting and how your clothes have started to sit, rather than anything the scale says.
Keeping the weight off, once the drug has done the easy part, is its own project, and it helps to hear it from someone who has been through the whole arc. Simon, an Italian businessman in his forties who asked to stay anonymous, started on a low dose of Mounjaro as, in his words, an act of self-care, and found that the drug was less the answer than the opening. “I took it as an opportunity to broaden my self-care and engage in regular training, which was the very first time,” he says. “I slowly reduced the things I thought were affecting my weight, starting with carbs, then sweets. I kept the discipline going, and I became quite regular and fit.” He lost around thirteen kilos and several sizes, but the part he returns to is not the weight. “As of today, it’s my discipline in training and food that sustain my weight and my well-being.” The injection, in other words, did the subtraction; the training is what made it stick.
Where food starts working with the drug
Up to here, food has been playing defence, protecting what the medication would otherwise strip away. Fibre is where it changes sides (read about fibre and how to get more of it here) and begins working with the drug rather than merely around it. The injection makes you feel full by acting on a satiety system your gut already runs: fermentable fibres, once the bacteria in your gut have broken them down, prompt your own body to release the very fullness hormones the drug is imitating, so you end up, on a good day, with the drug’s signal and a little of your own beneath it.
The fibres that manage this best are the slow ones, already abundant in rajma and chana, whole unhulled dals, root vegetables, and in the resistant starch that forms when rice or potato is cooked and then left to cool. Yesterday’s rice, taken from the fridge and reheated, is better at this than rice eaten straight from the pot (and here’s why), which is a small and pleasing licence to cook extra. Eaten alongside high-volume, low-calorie things like fruit, vegetables and salad, they give you a great deal of fullness for very little. The one caution is to build the fibre up gradually and drink more water as you go, or you will trade hunger for bloating, which is a rubbish exchange. A measured, consistent increase here helps most, as long as it stays gradual rather than enthusiastic.
There is a less-discussed benefit that has nothing to do with the number on the scale, and Simon puts it better than most. “I’m a businessman, I’m very busy, and my brain is my main asset,” he says. “My ability to see clearly was often influenced by hunger.” What the drug quietened for him was less appetite than distraction. “People talk about microdosing helping with mental clarity, and I get it. It’s not really a psychological effect, it’s simply that it reduces what I call the food noise.” That phrase, food noise, has become the shorthand for the constant low hum of thinking about the next meal that these drugs seem to switch off, and for some people it matters as much as the weight.
A brand-new European consensus statement, published in The Lancet Diabetes & Endocrinology this July by the obesity, dietetic and patient bodies EASO, EFAD and ECPO, wants clinicians to watch out for exactly this. When that ‘food noise’ goes silent, it’s not always a relief. Food, as we all well know, is so much more than mere sustenance. It can be comfort, reward, celebration… and so removing desire or thinking around it can create a void that’s not always good. The consensus recommends screening for these shifts, in mood, in coping, in how people relate to eating and to their own bodies, rather than treating a suppressed appetite as an unambiguous win. It also recommends screening for alcohol use disorders before starting, since the same pathways are involved.
When you’re doing everything right
Not everyone who ends up on one of these drugs is looking for a dramatic transformation. Some arrive at it from the opposite direction, having done everything the wellness playbook asks and watched it stop working anyway.
One woman I spoke to, forty-four, describes exactly this. She trains hard and trains well, progressive overload, a coach, the sessions logged and the loads climbing. She eats enough protein and sleeps her seven or eight hours. On paper, she is the model of someone who should be lean and strong, and for years she was. Then came a slow, creeping weight gain that no amount of doing the right things seemed to touch, the kind that arrives in the years around perimenopause, though in her case the bloodwork stubbornly refuses to confirm that’s what it is. What it added up to was months of working harder for worse results, which is its own particular kind of demoralising, because there’s no obvious lever left to pull when you’re already pulling all of them.
It wasn’t only the scale. She talks about inflammation, a body that felt puffy and reactive in a way it hadn’t before, and gut issues creeping in alongside the weight, the sense of a system slightly at war with itself. This is worth naming, because the conversation around these drugs is so fixated on fat that it misses the people whose real complaint is that their body has stopped feeling like theirs.
She went on to use the drug at a very low dose, well below the standard prescribed amount, a practice that has picked up the popular name microdosing. The term is worth pausing on, because it is a consumer coinage rather than a medical one, and the manufacturers explicitly do not endorse it. What people mean by it is taking a fraction of the usual therapeutic dose, in the hope of getting some of the metabolic and appetite benefit while sidestepping the harsher side effects, the nausea and the gut distress, that tend to come with full doses. Some people settle at a low dose deliberately; others are really describing the early titration steps that every prescription starts with anyway.
Simon’s own path is a case study in how far this can drift from the label. Fourteen months on, he takes roughly an eighth of a standard dose every three weeks, having stretched the interval out from weekly to monthly and beyond, and never returned for his scheduled follow-ups. “I still have syringes left,” he says, “because I started reducing the intake to a fraction of what it was supposed to be.” He has held his loss steady this way, and for him it has worked. It is also, precisely, the kind of self-directed dosing that the evidence hasn’t validated and that no prescriber signed off on, which is the tension running under the whole microdosing conversation: people are finding their own protocols faster than the science can assess them.
That same European consensus recommends dose-scaling led by a dietitian or clinician to reduce the nausea and gut distress that cause so many people to abandon the drugs early. But moving a dose downward with supervision is the recognised clinical practice; the evidence does not support doing it alone. These drugs were trialled at specific doses; the low ranges people are improvising are under-studied, and a protocol assembled from a forum thread and a friend with spare syringes is very much not the same thing as a titration plan.
Living with a slower stomach
Most of the discomfort people report in the early weeks, and after every dose increase, traces back to this same slowed stomach: the nausea, the reflux, the odd experience of feeling overfull three bites into a meal. A surprising amount of it is governed by how you eat rather than by what you eat. Smaller meals taken more often sit far better than three large ones arriving in a stomach in no rush to empty. Eating slowly and stopping at the first real hint of fullness matters too, because the signal now arrives late, and overshooting it is exactly what tips comfort into queasiness. Keeping meals lighter on fat while you are feeling rough helps, since fat slows the stomach even further; staying upright after eating rather than lying down eases reflux; and ginger, as adrak in your chai or simply chewed, works well against nausea. A short walk after a meal, even five or ten minutes around the block or in your living room, will help the food move along and take the edge off the rise in blood sugar that follows a meal.
Faster is not the prize
There are a few other small habits worth incorporating if they’re not already part of your everyday routine. The body handles food better earlier in the day, so a fuller breakfast and lunch with a lighter dinner will sit more comfortably. Sleep matters more than it is usually given credit for, too: seven to nine hours, because short nights push the appetite hormones in unhelpful directions and undo some of what the drug is doing. Plus, the instinct that faster is better is erroneous. Losing weight too quickly raises the risk of gallstones sharply, which is why the steadier half a kilo to a kilo a week that these drugs tend to produce when used sensibly is the gentler and smarter road. One thing worth saying plainly, since better eating can lower your blood sugar on its own: if you are also on insulin or other diabetes medication, talk to whoever prescribes it before you change how you eat in any significant way.
What it takes to use one of these responsibly
Nothing in this piece is an argument for going on a GLP-1. It is an argument that if you are on one, you should be getting the most from it and the least harm, and that second half depends almost entirely on how you go about it.
The first rule is that these are prescription drugs and belong in the hands of a doctor, start to finish. That sounds obvious, and yet the ease of access now, the online forms, the pharmacies that barely blink, the generic price collapse, means a great many people are effectively self-prescribing, titrating by anecdote and adjusting by feel. A community of strangers who are also guessing is not a substitute for someone who can see your bloodwork.
The second is monitoring. Responsible use means a baseline before you start, your vitals, your relevant bloodwork, and then regular checks, monthly to begin with, so that anything the drug is doing to your body is being watched by someone qualified to interpret it. These drugs affect far more than appetite, and the point of monitoring is to catch the things you cannot feel. Micronutrients are the clearest example; when you suddenly begin to eat dramatically less, you also absorb dramatically less, so iron, B12 and a handful of others can drift downward over months even as your weight is also doing that drift. This means the first sign of trouble is often fatigue, and the European consensus is clear that nutritional adequacy, protein, vitamins and minerals together, needs to be actively managed rather than assumed, ideally with a dietitian involved. It also asks for body composition and functional capacity to be tracked, not simply weight, since a number falling tells you nothing about which tissue is leaving. If your prescriber is only weighing you, ask for more.
The third is the hard contraindications, which are not negotiable and are exactly the sort of thing a prescriber exists to check. If you or a close family member have a history of medullary thyroid carcinoma, or the genetic condition MEN2, these drugs are off the table entirely, a boxed warning, not a footnote. A history of pancreatitis is a serious conversation to have before starting rather than an automatic bar, and pregnancy, or trying for it, means coming off well in advance. None of these are things you can (or should) assess on your own, and they are the reason a doctor is not optional.
And the last point is that a drug this powerful deserves respect rather than casualness. The culture around it has made it feel like a lifestyle choice, something to microdose for a wedding or cycle on and off around a holiday. It is a serious intervention in a serious system; stopping, pausing, lowering the dose, what happens to appetite and weight afterwards, what support exists at that point, all of it should be a real conversation with your prescriber, decided with you and up front, rather than something worked out in a panic eighteen months later when supply runs short, or the cost becomes untenable, or you simply decide you have had enough. An exit plan is not pessimism about the treatment. It is the difference between finishing a course of something and falling off the end of it.
Until very recently, these drugs were expensive, the better part of twenty thousand rupees a month, which meant that only certain income brackets were likely to sign up. That has now gone. Novo Nordisk’s patent on semaglutide lapsed in India in March, the generics arrived almost the same week, and dozens of brands are already competing on price, some starting doses down near a tenth of what the originals cost, so a great many more people, across many more cities, with far less guidance from a specialist at their elbow, are now on them, or about to be.
What does not come in the box is any of the above: the protein eaten first, the resistance band by the door, the gentler pace, the walk after dinner… These determine whether you reach the far side strong or simply smaller. More of us will be on these drugs every year, which is all the more reason to understand that the medicine does the losing, but the living well around it is still, as it always has been, done by hand.
1,000 Ways to Live Well is a Mille publication. Mille is a modern nutrition brand built around everyday rituals, starting with protein that doesn't ask you to compromise on taste. millesupergrain.com